Clinical Trial Search

Primary: Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan…

Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) — -8.7; -3.6 mmHg — p=<.001

Primary: Postoperative Atrial Fibrillation — 27.2; 27.8; 25.9 percentage of patients — p=0.95

Primary: Mean Post-Traumatic Stress Questionnaire-Military (PCL-M) Score — 53.8; 56.7; 48.8; 50.4 Score

Primary: Number of Outpatient Visits — 13 units on a scale

Primary: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12. — -5.3; -14.6; -25.1; -27.2 mg/dL — p=0.1819

Primary: Change in Pain Score — 2.4 units on a scale

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 87.2; 87.1; 84.6; 25.6 percentage of participants

Primary: Immunogenicity - Geometric Mean Titer Fold Increase From Baseline — 3.5; 4.0; 4.5; 3.4 GMT fold increase

Primary: Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes) — 7.4; 6.7; 8.5; 7.5 units on a scale

Primary: Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter — 55.28; 114.08; 246.00; NA ng/mL

Primary: Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — 0.081; 0.049; -0.083 liters — p=0.001

Primary: Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher — 32; 59 percentage of participants

Primary: Number of Participants With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR) — 0; 0 participants

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — 5.17; -28.02 percentage of Baseline — p=<0.001